Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/JCO.2010.32.1927 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
International web-based survey of patients with non-hydrocephalic symptomatic pineal cysts.
Acta Neurochir (Wien)
December 2024
Department of Neurosurgery, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
Objectives: To report the results of an international patient-reported survey that adds to the growing body of evidence surrounding the role of surgery in the management of a subset of patients with non-hydrocephalic symptomatic pineal cyst.
Design: An international web-based survey of health outcomes in patients with nhSPC.
Subjects: All survey participants who self-reported a diagnosis of symptomatic pineal cyst without hydrocephalus after radiological imaging.
A novel skin-like patch based on 3D hydrogel nanocomposite of Polydopamine/TiO nanoparticles and Ag quantum dots accelerates diabetic wound healing compared to stem cell therapy.
J Tissue Viability
December 2024
Institute of Nanoscience & Nanotechnology, Kafrelsheikh University, Kafr ElSheikh, 33516, Egypt; Nile Valley University, Fayoum, 63518 Egypt. Electronic address:
Despite the advances in the development of therapeutic wearable wound-healing patches, lack self-healing properties and strong adhesion to diabetic skin, hindering their effectiveness. We propose a unique, wearable patch made from a 3D organo-hydrogel nanocomposite containing polydopamine, titanium dioxide nanoparticles, and silver quantum dots (PDA-TiO@Ag). The designed patch exhibits ultra-stretchable, exceptional-self-healing, self-adhesive, ensuring conformal contact with the skin even during movement.
View Article and Find Full Text PDFVenetoclax Plus Intensified Chemoimmunotherapy as a Bridge to Allogeneic Stem Cell Transplantation in Richter Syndrome: Report of Two Cases.
Hematol Rep
December 2024
Oncohematology Division, IEO European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy.
Richter syndrome (RS) represents a major unmet need in the lymphoma field, being refractory to chemoimmunotherapy and targeted agents. The BCL-2 inhibitor venetoclax in combination with dose-adjusted EPOCH-R chemoimmunotherapy showed promising efficacy in patients affected by RS. However, responses were not durable, suggesting the need for further treatment optimization.
View Article and Find Full Text PDFEffectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 hospitalization related to the JN.1 variant in Europe: a test-negative case-control study using the id.DRIVE platform.
EClinicalMedicine
January 2025
P95 Epidemiology and Pharmacovigilance, Koning Leopold III Laan 1, Leuven 3001, Belgium.
Background: Prior studies have reported lower effectiveness of XBB.1.5-adapted vaccines against hospitalization related to the Omicron JN.
View Article and Find Full Text PDFA Phase I Study of Romidepsin in Combination With Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed or Refractory Aggressive Lymphomas Enriched for T-Cell Lymphomas.
Clin Lymphoma Myeloma Leuk
December 2024
Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO. Electronic address:
Introduction: Histone deacetylase inhibitors (HDACi) and combination chemotherapy are independently used to treat relapsed/refractory (R/R) lymphoma. In vitro studies suggest that the addition of HDACi to platinum-based chemotherapy is synergistic.
Patients And Methods: We conducted a phase I study of romidepsin, gemcitabine, oxaliplatin and dexamethasone (Romi-GemOxD) in R/R aggressive lymphomas with an expansion cohort in T-cell lymphomas.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!